Business
Currency:USD
2025/Q1
Stock NameRevenueRatio
Cystic fibrosis franchise195.12M34.34%
Other products157.84M27.78%
Evrysdi51.78M9.11%
Tremfya38.13M6.71%
Trelegy34.78M6.12%
TYSABRI31.33M5.51%
Voranigo30.53M5.37%
Other royalty income and revenues28.76M5.06%
View all
Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States2.26B100.00%